12-Nov-2026 13:14:05

CAPLIPOINTExpansion

CAPLIN POINT LABORATORIES Q2 FY27: ₹1,000+ CR CAPEX PROGRAMME, 50% INVESTMENTS NEARING COMPLETION; ONCOLOGY API PLANT TARGETED CY27, OSD FACILITY Q1 FY28 & NEW INJECTABLE PLANT Q2 FY28

• Capex Programme: Allocated over ₹1,000 Cr for manufacturing expansion, with approximately 50% of investments nearing completion. • Investment Timeline: Remaining investments expected to be completed over the next two years, with projects targeted for full commercialisation within one year of completion. • Caplin Plant I: Completed lyophilised injectables and dual-chamber syringe facility at Puducherry. • API Expansion: Completed Visakhapatnam API facility upgradation for existing and regulated markets. • Oncology Facility: Completed Kakkalur OSD and injectable facility for existing and regulated markets. • Oncology API Plant: Civil construction completed at Thervoy SIPCOT, Chennai, with project completion targeted in CY27. • OSD & Dermatology Expansion: Puducherry facility under construction, targeting Q1 FY28 completion for Mexico, Brazil, US and EU markets. • Injectables & Ophthalmic Expansion: New COL facility at Gummidipoondi, Chennai, targeting completion in Q2 FY28. • Capacity Expansion: Investments aimed at increasing manufacturing capacity, expanding product portfolios and strengthening backward integration. • Funding Strategy: Entire capex programme to be funded through internal accruals, with management expecting to remain cash-positive throughout. • Management Outlook: Focused on accelerating regulated-market expansion, commercialising new facilities and strengthening long-term growth through oncology, APIs and complex injectables.

CAPLIN POINT LAB LTD.

← Back to feed